Skip to main content
. 2026 Jan 14;37:102783. doi: 10.1016/j.mtbio.2026.102783

Fig. 8.

Fig. 8

Convergent in vitro-in vivo validation confirms HSP70 as a principal target of PDA-HP/NIR therapy. (A, C) Immunofluorescence staining of HSP70 in different treatment groups. Quantification of mean fluorescence intensity is shown in (C). Data are presented as mean ± SD (n = 6, ∗∗∗∗ p < 0.0001). Scale bars are 50 μm. (B, D) Immunofluorescence staining of cleaved caspase-3 (C-cas3) in different treatment groups. Quantification of mean fluorescence intensity is shown in (D). Data are presented as mean ± SD (n = 6, ∗∗ p = 0.0062, and ∗∗∗∗p < 0.0001). Scale bars are 20 μm. (E–H) Western blot analysis of HSP70, Bcl-2, Bax, and β-actin in spinal cord tissues. Quantification of protein expression levels are shown in (F–H). Data are presented as mean ± SD (n = 3, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001).